Cargando…

Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo

Background: Delirium, an acute decline in attention and global cognitive dysfunction, occurs frequently following cardiac surgery and has been demonstrated to be significantly associated with cognitive dysfunction and reduced functional ability. In the DEXACET trial, we demonstrated a significant re...

Descripción completa

Detalles Bibliográficos
Autores principales: Khera, Tanvi, Helfand, Jordan, Kelly, Lauren, Mueller, Ariel, Shankar, Puja, Marcantonio, Edward R., Subramaniam, Balachundhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980856/
https://www.ncbi.nlm.nih.gov/pubmed/35392551
http://dx.doi.org/10.3389/fphar.2022.803903
_version_ 1784681487888547840
author Khera, Tanvi
Helfand, Jordan
Kelly, Lauren
Mueller, Ariel
Shankar, Puja
Marcantonio, Edward R.
Subramaniam, Balachundhar
author_facet Khera, Tanvi
Helfand, Jordan
Kelly, Lauren
Mueller, Ariel
Shankar, Puja
Marcantonio, Edward R.
Subramaniam, Balachundhar
author_sort Khera, Tanvi
collection PubMed
description Background: Delirium, an acute decline in attention and global cognitive dysfunction, occurs frequently following cardiac surgery and has been demonstrated to be significantly associated with cognitive dysfunction and reduced functional ability. In the DEXACET trial, we demonstrated a significant reduction in postoperative in-hospital delirium with intravenous (IV) acetaminophen when compared with placebo. In this analysis we examined whether this protective association also extended to 12 month cognitive and functional outcomes. Methods: This study was a prospective, randomized, placebo-controlled, triple-blinded, factorial design trial conducted at Beth Israel Deaconess Medical Center, approved by the IRB. In this trial, 120 older cardiac surgical patients were randomly assigned to receive either intravenous (IV) acetaminophen or placebo in addition to propofol or dexmedetomidine. Those receiving IV acetaminophen displayed a significant reduction in in-hospital delirium. We collected cognitive, mood and functional outcome data using the Montreal Cognitive Assessment, telephone version (T-MoCA), Geriatric Depression Scale (GDS) and the Basic and Instrumental Activities of Daily Living (ADLs, IADLs) at 1 month and 12 months after surgery. Results: Of the 120 enrolled patients in the primary trial, 93 (77.5%) and 83 (69.2%) patients responded to assessments at 1 month and 12 months, respectively. No statistically significant differences in median T-MoCA scores were observed between acetaminophen and placebo groups at 1 month (18.0 vs.18.0, p = 0.52) or 12 months (19.0 vs.18.0, p = 0.62) following surgery. There were similarly no differences in GDS, ADLs or IADLs between treatment groups. Losses to follow-up limited the sample sizes and 10 of the 23 (45%) original study participants who had postoperative delirium were lost to follow up. Conclusion: Administration of intravenous acetaminophen was not associated with a difference in long term cognitive or functional status following cardiac surgery. Additional research on long-term outcomes following postoperative delirium with a larger sample size and improved cohort retention strategies will be needed to address this important area.
format Online
Article
Text
id pubmed-8980856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89808562022-04-06 Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo Khera, Tanvi Helfand, Jordan Kelly, Lauren Mueller, Ariel Shankar, Puja Marcantonio, Edward R. Subramaniam, Balachundhar Front Pharmacol Pharmacology Background: Delirium, an acute decline in attention and global cognitive dysfunction, occurs frequently following cardiac surgery and has been demonstrated to be significantly associated with cognitive dysfunction and reduced functional ability. In the DEXACET trial, we demonstrated a significant reduction in postoperative in-hospital delirium with intravenous (IV) acetaminophen when compared with placebo. In this analysis we examined whether this protective association also extended to 12 month cognitive and functional outcomes. Methods: This study was a prospective, randomized, placebo-controlled, triple-blinded, factorial design trial conducted at Beth Israel Deaconess Medical Center, approved by the IRB. In this trial, 120 older cardiac surgical patients were randomly assigned to receive either intravenous (IV) acetaminophen or placebo in addition to propofol or dexmedetomidine. Those receiving IV acetaminophen displayed a significant reduction in in-hospital delirium. We collected cognitive, mood and functional outcome data using the Montreal Cognitive Assessment, telephone version (T-MoCA), Geriatric Depression Scale (GDS) and the Basic and Instrumental Activities of Daily Living (ADLs, IADLs) at 1 month and 12 months after surgery. Results: Of the 120 enrolled patients in the primary trial, 93 (77.5%) and 83 (69.2%) patients responded to assessments at 1 month and 12 months, respectively. No statistically significant differences in median T-MoCA scores were observed between acetaminophen and placebo groups at 1 month (18.0 vs.18.0, p = 0.52) or 12 months (19.0 vs.18.0, p = 0.62) following surgery. There were similarly no differences in GDS, ADLs or IADLs between treatment groups. Losses to follow-up limited the sample sizes and 10 of the 23 (45%) original study participants who had postoperative delirium were lost to follow up. Conclusion: Administration of intravenous acetaminophen was not associated with a difference in long term cognitive or functional status following cardiac surgery. Additional research on long-term outcomes following postoperative delirium with a larger sample size and improved cohort retention strategies will be needed to address this important area. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8980856/ /pubmed/35392551 http://dx.doi.org/10.3389/fphar.2022.803903 Text en Copyright © 2022 Khera, Helfand, Kelly, Mueller, Shankar, Marcantonio and Subramaniam. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Khera, Tanvi
Helfand, Jordan
Kelly, Lauren
Mueller, Ariel
Shankar, Puja
Marcantonio, Edward R.
Subramaniam, Balachundhar
Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo
title Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo
title_full Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo
title_fullStr Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo
title_full_unstemmed Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo
title_short Twelve-Month Cognitive and Functional Outcomes Following Cardiac Surgery: The DEXACET Trial of Intravenous Acetaminophen Versus Placebo
title_sort twelve-month cognitive and functional outcomes following cardiac surgery: the dexacet trial of intravenous acetaminophen versus placebo
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980856/
https://www.ncbi.nlm.nih.gov/pubmed/35392551
http://dx.doi.org/10.3389/fphar.2022.803903
work_keys_str_mv AT kheratanvi twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo
AT helfandjordan twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo
AT kellylauren twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo
AT muellerariel twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo
AT shankarpuja twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo
AT marcantonioedwardr twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo
AT subramaniambalachundhar twelvemonthcognitiveandfunctionaloutcomesfollowingcardiacsurgerythedexacettrialofintravenousacetaminophenversusplacebo